Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.
作者信息
Deeg H Joachim
机构信息
Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA.
出版信息
Blood Adv. 2022 Mar 8;6(5):1623-1627. doi: 10.1182/bloodadvances.2021004799.
Abstract
摘要
相似文献
1
Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.
Blood Adv. 2022 Mar 8;6(5):1623-1627. doi: 10.1182/bloodadvances.2021004799.
2
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
3
Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.
Blood Adv. 2022 Mar 8;6(5):1619-1622. doi: 10.1182/bloodadvances.2021004829.
4
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
Ann Hematol. 2017 Mar;96(3):469-478. doi: 10.1007/s00277-016-2909-2. Epub 2017 Jan 6.
5
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
J Hematol Oncol. 2021 Jan 6;14(1):4. doi: 10.1186/s13045-020-01017-7.
6
A case report of the second de novo acute myeloid leukemia (AML) following allogeneic stem cell transplantation in a patient with the first AML.
Korean J Intern Med. 2010 Mar;25(1):110-3. doi: 10.3904/kjim.2010.25.1.110. Epub 2010 Feb 26.
7
The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.
Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.
8
Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Hematology. 2021 Dec;26(1):340-347. doi: 10.1080/16078454.2021.1905356.
9
Outcomes of adult patients with acute myeloid leukemia and unsuccessful cytogenetic analysis undergoing allogeneic hematopoietic stem cell transplantation.
Hematol Oncol Stem Cell Ther. 2021 Jun;14(2):134-140. doi: 10.1016/j.hemonc.2020.09.001. Epub 2020 Oct 8.
10
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.
引用本文的文献
1
Clinical profile of -ITD mutation in West Algerian population with acute myeloid leukemia.
Mol Biol Res Commun. 2024;13(3):175-182. doi: 10.22099/mbrc.2024.49437.1955.
2
Theranostics in Hematooncology.
J Nucl Med. 2023 Jul;64(7):1009-1016. doi: 10.2967/jnumed.122.265199. Epub 2023 Jun 8.
3
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).
Cancers (Basel). 2023 Apr 24;15(9):2441. doi: 10.3390/cancers15092441.
4
Genomic Alterations, Gene Expression Profiles and Functional Enrichment of Normal-Karyotype Acute Myeloid Leukaemia Based on Targeted Next-Generation Sequencing.
Cancers (Basel). 2023 Feb 22;15(5):1386. doi: 10.3390/cancers15051386.
5
Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Cancer Med. 2023 Apr;12(8):9332-9350. doi: 10.1002/cam4.5690. Epub 2023 Feb 17.
本文引用的文献
1
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Blood. 2021 Jul 22;138(3):273-282. doi: 10.1182/blood.2021011281.
2
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
Leukemia. 2021 Nov;35(11):3044-3058. doi: 10.1038/s41375-021-01277-3. Epub 2021 Jun 25.
3
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
J Clin Oncol. 2021 Aug 10;39(23):2535-2538. doi: 10.1200/JCO.21.00067. Epub 2021 May 27.
4
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Front Immunol. 2021 May 3;12:659595. doi: 10.3389/fimmu.2021.659595. eCollection 2021.
5
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. doi: 10.1016/j.jtct.2021.02.031. Epub 2021 Feb 26.
6
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
J Clin Oncol. 2021 Feb 10;39(5):419-432. doi: 10.1200/JCO.20.00475. Epub 2021 Jan 12.
7
Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark.
J Clin Oncol. 2021 Mar 10;39(8):870-875. doi: 10.1200/JCO.20.03142. Epub 2021 Jan 7.
8
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
J Natl Compr Canc Netw. 2021 Jan 6;19(1):16-27. doi: 10.6004/jnccn.2021.0002.
9
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24.
10
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
Nat Med. 2020 Dec;26(12):1852-1858. doi: 10.1038/s41591-020-1089-8. Epub 2020 Oct 26.
Zotero 插件